Mechanisms of action of currently used antiseizure drugs.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacological mechanisms without systematic review methodology or primary clinical trial data.
PubMed 32120063 · doi:10.1016/j.neuropharm.2020.107966
What was done
This narrative review summarizes the pharmacological mechanisms of action of currently available antiseizure drugs (ASDs) and discusses the potential development of targeted therapies for genetic epilepsies based on emerging pathophysiological findings.
What was found
The abstract reports no quantitative data. It categorizes currently prescribed ASDs into four primary mechanisms: (1) modulation of voltage-gated ion channels (sodium, calcium, and potassium); (2) enhancement of GABA-mediated inhibitory neurotransmission; (3) attenuation of glutamate-mediated excitatory neurotransmission; and (4) presynaptic modulation of neurotransmitter release. The author notes that existing agents suppress seizure generation and spread without exhibiting disease-modifying properties, while precision small-molecule, antisense, and gene therapies are under development for select genetic epilepsy syndromes.
Why it matters
It provides a foundational framework for understanding how standard antiseizure medications modulate neuronal excitability and outlines the therapeutic transition toward disease-modifying, etiology-targeted treatments.
Limits
The paper is a non-systematic narrative review containing no primary experimental or clinical trial data, quantitative effect sizes, or comparative efficacy metrics. It does not address long-term clinical outcomes, adverse event profiles, or the management of non-genetic epilepsies.
Cited by
- supports Vigabatrin is an anti-seizure medication that acts through GABAergic mechanisms.